orantinib has been researched along with Chondrosarcoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdollahi, A; Bertl, E; Ewerbeck, V; Gebhard, MM; Huber, PE; Klenke, FM; Sckell, A | 1 |
1 other study(ies) available for orantinib and Chondrosarcoma
| Article | Year |
|---|---|
Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; Chondrosarcoma; Disease Models, Animal; Indoles; Injections, Subcutaneous; Male; Mice; Mice, SCID; Microcirculation; Oxindoles; Propionates; Pyrroles; Treatment Outcome | 2007 |